Ovid Therapeutics (OVID) Cash & Equivalents (2016 - 2026)

Ovid Therapeutics has reported Cash & Equivalents for 11 years, with the latest figure at $94.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 345.04% year-over-year to $94.1 million; the trailing twelve-month figure through Mar 2026 stood at $94.1 million (up 345.04% YoY), and the FY2025 full-year result was $12.6 million, down 51.95% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $94.1 million, up from $12.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $166.7 million in Q1 2022, with the low at $12.6 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $48.5 million across 5 years, with a median of $29.5 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 77.63% — and 2026, when it soared 345.04%.
• Ovid Therapeutics' Cash & Equivalents stood at $42.0 million in 2022, then sank by 35.64% to $27.0 million in 2023, then slipped by 2.74% to $26.3 million in 2024, then slumped by 51.95% to $12.6 million in 2025, then soared by 644.35% to $94.1 million in 2026.
• The last three Cash & Equivalents figures came in at $94.1 million (Q1 2026), $12.6 million (Q4 2025), and $20.5 million (Q3 2025), per Business Quant data.